Catalyst Wire Dossier Catalyst Wire Dossier

SOF/VEL/VOX

sofosbuvir/velpatasvir/voxilaprevir · Gilead Sciences
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for SOF/VEL/VOX, covering 2017-11-06 to 2022-07-21. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis [Phase 4]

See pricing